Urothelial Cancer Clinical Trials

Find Urothelial Cancer Clinical Trials Near You

A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants With Low Grade Upper Tract Urothelial Carcinoma (SURF303)

Status: Recruiting
Location: See all (32) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Participants ≥ 18 years of age at the time of informed consent and willing and able to comply with all required study procedures

• Confirmed LG UTUC (both favorable and unfavorable) per AUA

• At least 5mm of marker lesion(s) left behind

• Identification of marker lesion(s) within 8 weeks prior to randomization (refer to Inclusion Criterion #2)

• If synchronous NMIBC, NMIBC must be fully resected and low-grade Ta or T1

• No prior BCG administration within 1 year of date of consent.

• No intravesical chemotherapy within 8 weeks prior to C1D1 (including UGN-101).

• No systemic chemotherapy within 3 months prior to C1D1

• ECOG PS 0-2

• Pathology consists of pure urothelial carcinoma

• Adequate bone marrow function:

• i. Absolute neutrophil count (ANC) ≥1,500/mm3 ii. Platelet count ≥75,000/mm3 iii. Hemoglobin ≥10.0 g/dL

• Adequate liver function:

• i. Total bilirubin ≤ ULN ii. Alanine aminotransferase (ALT) ≤ ULN iii. Aspartate aminotransferase (AST) ≤ ULN

• Adequate renal function:

• i. Estimated glomerular filtration rate \>30 mL/min ii. Serum Phosphate level ≤ ULN prior to starting treatment iii. International normalized ratio (INR) ≤1.5 × ULN

Locations
United States
California
Loma Linda University (LLU) - Loma Linda University Medical Center (LLUM)
RECRUITING
Loma Linda
USC Norris Comprehensive Cancer Center
RECRUITING
Los Angeles
Florida
Moffitt Cancer Center
RECRUITING
Tampa
Georgia
The Winship Cancer Institute of Emory University
RECRUITING
Atlanta
Illinois
Duly Health and Care Chicago
RECRUITING
Lisle
Indiana
Urology of Indiana, LLC
RECRUITING
Greenwood
Indiana University (IU) Health Physicians - Urology
RECRUITING
Indianapolis
First Urology
RECRUITING
Jeffersonville
Massachusetts
Greater Boston Urology - Plymouth Care Center
RECRUITING
Plymouth
Michigan
University of Michigan Health System (UMHS)
RECRUITING
Ann Arbor
Michigan Healthcare Professionals - William Beaumont University Hospital
RECRUITING
Royal Oak
Missouri
Urology of St. Louis
RECRUITING
St Louis
New Jersey
Summit Health - Washington Township
RECRUITING
Sewell
New York
Albany Medical College
RECRUITING
Albany
Associated Medical Professionals of NY, PLLC
RECRUITING
Syracuse
Ohio
Cleveland Clinic
RECRUITING
Cleveland
Central Ohio Urology Group
RECRUITING
Gahanna
Pennsylvania
Penn Medicine Radnor
RECRUITING
Radnor
South Carolina
Medical University of South Carolina (MUSC)
RECRUITING
Mt. Pleasant
Tennessee
Urology Associates, P C
RECRUITING
Nashville
Texas
Urology Austin - Apex Cancer Care - Austin
RECRUITING
Austin
The University of Texas Southwestern Medical Center
RECRUITING
Dallas
The University of Texas MD Anderson Cancer Center
RECRUITING
Houston
Other Locations
France
Hôpital Européen Georges Pompidou (HEGP)
RECRUITING
Paris
Hopital Pitie-Salpetriere
RECRUITING
Paris
Israel
Edith Wolfson Medical Center
RECRUITING
Holon
Hadassah University Hospital - Ein Kerem
RECRUITING
Jerusalem
Meir Medical Center
RECRUITING
Kfar Saba
Tel Aviv Sourasky Medical Center
RECRUITING
Tel Aviv
Spain
Hospital Universitario Puerta del Mar
RECRUITING
Cadiz
Hospital Universitario 12 de Octubre
RECRUITING
Madrid
Hospital Universitari i Politècnic La Fe
RECRUITING
Valencia
Contact Information
Primary
Lara Balick
TyraClinicalTrials@tyra.bio
929-792-5633
Time Frame
Start Date: 2025-12-22
Estimated Completion Date: 2030-11
Participants
Target number of participants: 285
Treatments
Experimental: Study Drug Dose Cohort A (DCA) 60mg
Dabogratinib (TYRA-300) monotherapy in Participants
Experimental: Study Drug Dose Cohort B (DCB) 80mg
Dabogratinib (TYRA-300) monotherapy in Participants
Sponsors
Leads: Tyra Biosciences, Inc

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.